BrightSpring Health Services, Inc. Reports Robust Second Quarter 2026 Results, Raises Full-Year Guidance
Louisville, KY, July 31, 2026 – BrightSpring Health Services, Inc. (NASDAQ: BTSG), a leading provider of home and community-based health services, has delivered an impressive set of financial results for the second quarter ended June 30, 2026. The company also announced an upward revision to its full-year 2026 revenue and Adjusted EBITDA guidance, signaling continued momentum and strong operational execution.
Key Financial Highlights for Q2 2026
- Net Revenue: \$3,873 million, up 23.0% from \$3,148 million in Q2 2025.
- Gross Profit: \$493 million, an increase of 31.5% from \$375 million in Q2 2025.
- Net Income: \$87 million, a substantial rise compared to \$9 million in Q2 2025.
- Adjusted EBITDA: \$206 million, up 44.2% from \$143 million a year ago.
- Leverage Ratio: Improved to 2.15x as of June 30, 2026, from 2.27x on March 31, 2026.
- Debt Repayment: \$300 million payment and concurrent modification of the First Lien Facility, resulting in interest savings.
- Shareholder Actions: Completion of an underwritten secondary offering of common stock by affiliates of Kohlberg Kravis Roberts & Co. L.P. and certain management members in June 2026. Simultaneous \$60 million repurchase of 1,026,465 shares of common stock from the underwriter.
Segment Performance
| Segment | Q2 2026 Revenue (\$M) | Q2 2025 Revenue (\$M) | Growth (%) | Q2 2026 EBITDA (\$M) | Q2 2025 EBITDA (\$M) | Growth (%) |
|---|---|---|---|---|---|---|
| Pharmacy Solutions | 3,407 | 2,790 | 22% | 180 | 125 | 44% |
| Provider Services | 466 | 358 | 30% | 75 | 56 | 33% |
| Total | 3,873 | 3,148 | 23% | 255 | 181 | 41% |
Business Metrics
- Pharmacy Solutions: Prescriptions dispensed were largely flat at 10.84 million, while revenue per script rose sharply to \$314.20 (up 22%). Gross profit per script increased to \$27.50 (up 28%).
- Provider Services: Home Health Care average daily census soared by 54% to 46,448. Rehab Care persons served rose 9% to 7,755. Personal Care persons served remained stable at 16,357.
Balance Sheet and Cash Flow
- Cash & Cash Equivalents: \$550.4 million as of June 30, 2026 (up from \$88.4 million at year-end 2025).
- Accounts Receivable: \$1.14 billion (up from \$989.7 million).
- Inventories: \$575 million (down from \$815 million).
- Total Assets: \$5.99 billion (down from \$6.41 billion at year-end 2025 due to divestitures).
- Total Liabilities: \$3.93 billion (down from \$4.53 billion).
- Shareholders’ Equity: \$2.05 billion (up from \$1.88 billion).
BrightSpring made significant debt repayments (\$320.5 million for the six months), repurchased \$120 million of shares, and completed a major divestiture (Community Living business), contributing to higher cash reserves and reduced leverage.
Full-Year 2026 Guidance (Excludes Community Living Business)
- Revenues: \$15.1 billion to \$15.425 billion (up 17.0% to 19.5% year-over-year).
- Pharmacy Segment Revenue: \$13.2 billion to \$13.5 billion (up 15.3% to 17.9%).
- Provider Segment Revenue: \$1.90 billion to \$1.925 billion (up 29.7% to 31.4%).
- Total Adjusted EBITDA: \$820 million to \$845 million (up 32.8% to 36.8%).
- Amedisys and LHC branches acquisition: Expected to contribute ~\$35 million in Adjusted EBITDA in 2026.
This guidance demonstrates management’s confidence in continued growth, operational excellence, and successful integration of acquisitions.
Operational and Strategic Updates
- BrightSpring completed the divestiture of the Community Living business in March 2026, focusing results on continuing operations.
- Interest savings achieved through refinancing and modification of the First Lien Facility.
- Significant share buyback and secondary offering, which could affect share value and ownership structure.
- Strong growth in home health care, pharmacy solutions, and provider services metrics.
CEO Jon Rousseau emphasized the company’s quality focus, service level performance, and commitment to innovation and leadership in the industry, positioning BrightSpring for further growth and impact.
Risks and Forward-Looking Statements
- BrightSpring operates in a highly competitive industry and is subject to risks related to Medicare/Medicaid reimbursement, payment models, and regulatory changes.
- Potential impacts include changes in payor mix, government spending, drug utilization/pricing, supplier relationships, recruitment and retention of qualified staff, data security, and litigation.
- Company warns that actual results may differ materially from projections due to these factors.
- Significant debt, possible asset impairments, and exposure to macroeconomic or geopolitical events (pandemics, natural disasters, tariffs).
- Recent share repurchases, secondary offering, and acquisitions could materially affect share value.
Non-GAAP Measures
BrightSpring uses EBITDA, Adjusted EBITDA, and Adjusted EPS as supplemental measures of financial performance, citing their usefulness for comparing operating performance across periods. Investors are cautioned that these measures are not substitutes for GAAP metrics and may differ from similarly titled measures used by other companies.
Upcoming Investor Events
The company will host a conference call on July 31 at 8:30 a.m. ET. A live and archived webcast, as well as supplemental information, will be available on its investor relations website.
Conclusion
BrightSpring’s Q2 2026 results reveal strong revenue growth, significant profitability improvements, reduced leverage, and increased cash reserves. The company’s upgraded guidance, successful acquisitions, and share repurchase activity are all price-sensitive news for shareholders and could impact share value. Investors should monitor upcoming events and remain aware of the operational and regulatory risks highlighted by management.
Contacts
- Investor Relations: David Deuchler, CFA ([email protected], 917.209.5605)
- Media Contact: Leigh White ([email protected], 502.630.7412)
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review BrightSpring Health Services’ filings with the SEC and consult their own financial advisors before making investment decisions. Actual results, financial performance, and share value may differ materially from forward-looking statements due to risks and uncertainties outlined herein and in official company disclosures.
